Diabetes Clinical Trials in Dallas
View 167 new treatments for Diabetes in Dallas, TX, and nearby areas, such as Allen, Arlington, Carrollton, Denton, Frisco, Garland, Grand Prairie, Irving, Lewisville, McKinney and Mesquite. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Dallas + 2 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 3 - 12 Weeks
Glenn Crater, MD
Study Director
Doravirine for HIV
Research Clinic, Dallas + 2 more
This trial is testing doravirine, an HIV medication, in people with HIV who have abnormal cholesterol levels. The goal is to see if doravirine can help control HIV and improve cholesterol and heart health. Doravirine is a newly-approved antiretroviral.Show More
Recruiting
No Placebo Trial
Phase < 1
Est. 3 - 6 Weeks
Theodoros Kelesidis, MD PHD
Principal Investigator
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Dallas + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Samer Kaba, MD
Study Chair
Semaglutide for Type 2 Diabetes with Dialysis
Research Clinic, Irving + 4 more
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Ildiko Lingvay, MD, MPH, MSCS
Principal Investigator
Metformin for Prediabetes
Research Clinic, Dallas + 1 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial (COED Trial)
Research Clinic, Dallas + 1 more
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Ashkan M Abbey, MD
Principal Investigator
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Eli Lilly Clinic, Dallas + 2 more
This trial is testing a new medication called tirzepatide for people with type 2 diabetes. Tirzepatide helps control blood sugar by making the body produce more insulin and reducing appetite. The study aims to see if switching to this new treatment is more effective than current therapies.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Tirzepatide for Type 2 Diabetes
Eli Lilly Clinic, Dallas + 2 more
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Rifampin for Osteomyelitis in Diabetics
Research Clinic, Dallas + 1 more
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Mary T Bessesen, MD
Study Chair
Faricimab for Diabetic Macular Edema
Genentech Clinic, Willow Park + 2 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Clinical Trials
Study Director
Page 1 of 11
Frequently Asked Questions
Explore related conditions